
Anumana
Total Raised
$127.4MInvestors Count
6Deal Terms
1Funding, Valuation & Revenue
3 Fundings
Anumana has raised $127.4M over 3 rounds.
Anumana's latest funding round was a Series C for $95.4M on April 24, 2025.
Anumana's latest post-money valuation is from April 2025.
Sign up for a free demo to see Anumana's valuations in April 2025 and more.
Date | Round | Amount | Investors | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Revenue | Sources |
|---|---|---|---|---|---|---|
4/24/2025 | Series C | $95.4M | 3 | |||
11/17/2022 | Unattributed | |||||
6/7/2022 | Incubator/Accelerator |
Date | 4/24/2025 | 11/17/2022 | 6/7/2022 |
|---|---|---|---|
Round | Series C | Unattributed | Incubator/Accelerator |
Amount | $95.4M | ||
Investors | |||
Valuation | |||
Revenue | |||
Sources | 3 |
Anumana Deal Terms
1 Deal Term
Anumana's deal structure is available for 1 funding round, including their Series C from April 24, 2025.
Round | Series C |
|---|---|
Funding Date | |
Pre-Money Valuation | |
Post-Money Valuation | |
Amount Raised | |
Shares Authorized | |
Issuance Price | |
Dividend Rate | |
Liquidation Preferences | |
Liquidation Price | |
Participation | |
Conversion Price | |
Anti Dilution | |
General Voting | |
Board Voting | |
Par Value |
Round | Funding Date | Pre-Money Valuation | Post-Money Valuation | Amount Raised | Shares Authorized | Issuance Price | Dividend Rate | Liquidation Preferences | Liquidation Price | Participation | Conversion Price | Anti Dilution | General Voting | Board Voting | Par Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Series C |
Anumana Investors
6 Investors
Anumana has 6 investors. Mayo Clinic invested in Anumana's Series C funding round.
First funding | Last Funding | Investor | Rounds | Board Seats | Type | Location |
|---|---|---|---|---|---|---|
4/24/2025 | 4/24/2025 | 1 Series C | Non-Profit Foundation | Minnesota | ||
Corporate Venture | California | |||||
Asset/Investment Management | Russian Federation | |||||
Venture Capital | California | |||||
Corporation | Massachusetts |
First funding | 4/24/2025 | ||||
|---|---|---|---|---|---|
Last Funding | 4/24/2025 | ||||
Investor | |||||
Rounds | 1 Series C | ||||
Board Seats | |||||
Type | Non-Profit Foundation | Corporate Venture | Asset/Investment Management | Venture Capital | Corporation |
Location | Minnesota | California | Russian Federation | California | Massachusetts |
Anumana Acquisitions
1 Acquisition
Anumana acquired 1 company. Their latest acquisition was NeuTrace on November 07, 2022.
Date | Investment Stage | Companies | Valuation Valuations are submitted by companies, mined from state filings or news, provided by VentureSource, or based on a comparables valuation model. | Total Funding | Note | Sources |
|---|---|---|---|---|---|---|
11/7/2022 | Convertible Note | $9.8M | Acquired | 16 |
Date | 11/7/2022 |
|---|---|
Investment Stage | Convertible Note |
Companies | |
Valuation | |
Total Funding | $9.8M |
Note | Acquired |
Sources | 16 |
Compare Anumana to Competitors

Idoven is a health technology company that focuses on detection and medicine in the cardiovascular domain. The company offers an artificial intelligence (AI)-powered platform that improves the speed, consistency, and accuracy of electrocardiogram (ECG) interpretation and works with existing ECG devices to support clinician decision-making and disease management. It was founded in 2018 and is based in Madrid, Spain.

Powerful Medical focuses on artificial intelligence (AI) driven healthcare solutions within the medical diagnostics sector. The company provides the PMcardio platform, which uses artificial intelligence to interpret 12-lead electrocardiograms (ECGs) for the diagnosis of cardiovascular diseases. PMcardio's technology aims to assist healthcare professionals by improving diagnostic capabilities and facilitating care coordination. It was founded in 2017 and is based in Bratislava, Slovakia (Slovak Republic).

Cardiomatics operates in the healthcare technology sector, focusing on ECG analysis. The company provides automated long-term ECG interpretation and arrhythmia diagnostics using a cloud-based platform for ECG signal analysis and reporting. Cardiomatics serves cardiac clinics and service providers. It was founded in 2017 and is based in Krakow, Poland.

Cardiolyse is a cloud-based platform that provides Electrocardiogram and heart rate variability (HRV) analytics for the healthcare sector. The company offers services including remote heart health monitoring, detection of heart conditions, and predictions of cardiovascular events using machine-learning algorithms. Cardiolyse serves healthcare providers, insurance companies, and individuals at risk for heart disorders. It was founded in 2015 and is based in Helsinki, Finland.

Ultromics operates within the medical technology industry and focuses on heart failure detection. The company offers diagnostic tools that analyze echocardiograms to identify conditions such as heart failure with preserved ejection fraction (HFpEF) and cardiac amyloidosis, providing clinicians with reports to assist in clinical decisions. Ultromics serves healthcare providers, including hospitals and clinics, by integrating its technology into existing medical imaging workflows. It was founded in 2017 and is based in Oxford, England.
Abbott Cardiac Rhythm Management specializes in the development of medical devices and solutions for treating cardiovascular conditions. The company offers a range of products that assist in cardiac rhythm management, vascular health, and heart failure monitoring, designed to improve patient outcomes and support healthcare professionals. These products are primarily utilized within the healthcare sector, including hospitals, clinics, and by healthcare professionals specializing in cardiovascular care. It was founded in 2018 and is based in Abbott Park, Illinois.
Loading...

